image dons

I make a donation


Searching the rivaroxaban dosis which enables an adequate anticoagulation evaluated by the level of thrombin generated in patients suffering atrial fibrillation and having a successful percutaneous left atrial appendage closure.


La Grande Journée du Coeur (13 juin 2023)
Attention : plus que quelques places restantes !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

22e Colloquium (12 septembre 2023)
Inscrivez-vous dès maintenant !

logo étude


Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure

date de réalisation


nombre de patients


nombre de centres participants

National multicentric trial

type de financement

Privé (Fonds de Dotation Action & Bayer)



A study conducted by Fonds de Dotation ACTION
Find out details and results on the dedicated page

ADRIFT conducted by Fonds de Dotation ACTION

Autres études



En cours

To assess if flecainide is more efficient than standard of care (control group) to prevent AF occurrence during the 3 months after PFO closure.


En cours

Evaluation of Anakinra versus placebo in treatment of acute myocarditis and evaluation of the contuity of the reference treatment with IEC in patients without ventricular dysfunction ventriculaire.


En cours

Impact of genetics on occuring of coronary diseases in young patients and the pharmacogenetic of clopidogrel and its impact on the prognosis of patients having had angioplasty